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Background: Recently, a new subpopulation of T cells, the Th17 subset, has been implicated in autoim-
mune diseases. Its development is inﬂuenced by IL-27, expressed in macrophages or dendritic cells.
IL-27 blockage delays the onset of diabetes in non obese diabetes mouse, but its role in type 1 diabetes
(T1D) in human has not been reported yet. The aim of this study was identify variants in the entire coding
regions of IL-27 gene, including the 50 proximal region, and their possible association with the disease.
Methods: Those regions were ampliﬁed by polymerase chain reaction followed by automatic sequencing
and restriction fragments length polymorphisms. The cohort involved 614 individuals – 318 patients
with T1D (19.6 ± 11.2 y, 129 M/189F) and 296 healthy control subjects (30.3 ± 13.2 y, 131 M/165F).
Results: We identiﬁed eight allelic variants in the 50 proximal and coding regions of IL-27 gene, including
two new variants: the c.-324 C > T in the 50 proximal region and the c.521 G > C in exon 5. None of these
variants compromised transcription factor binding sites or the protein structure. The frequency of the
alleles and genotypes of IL-27 variants did not differ between T1D patients and controls. There was no
association between IL27 variants with gender, ethnicity, age at diagnosis of diabetes or presence of pan-
creatic and extrapancreatic autoantibodies.
Conclusion: Our ﬁndings suggest that allelic variants in IL27 are not associated with susceptibility to T1D
in a Brazilian population.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Type 1 diabetes mellitus (T1D) results from the progressive and
speciﬁc autoimmune destruction of insulin-secreting pancreatic
beta-cells, elicited by lymphocytes and inﬂammatory cytokines [1].
Recently, interleukin-27 (IL-27), a novel cytokine secreted by
stimulated antigen-presenting cells, has been identiﬁed as a regula-
tor of immune response. IL-27 is a heterodimeric cytokine member
of the IL-6/IL-12 family of type I cytokines, composed by EBI3 (Ep-
stein-Barr virus-induced gene 3 protein) and p28 (an IL-12 p35-re-
lated polypeptide) subunits [2]. The cellular effects of IL-27 are
mediated through a heterodimeric receptor complex expressed by
several cells including monocytes, T cells, B cells and ﬁbroblasts,
indicating that IL-27 may have pleiotropic functions [3].
IL-27 seems to have two distinct immune functions. As an initi-
ator of TH1 type immune response it promotes naïve T cell prolif-
eration [4] and is a potent inducer of IFN-c production,
participating in host defense against intracellular pathogen infec-Carboidratos e Radioimuno-
sidade de São Paulo, Av. Dr.
SP, Brazil. Tel.: +55 11 3061
Silva).
evier OA license.tions [5] .Upregulation of IL-27 has been noted in granulomatous
diseases [6], inﬂammatory bowel disease [7] and in mouse models
of uveitis and multiple sclerosis [8]. As an attenuator of immune
inﬂammatory responses, IL-27 suppresses the expansion of effector
and memory T cells and inhibits cytokine secretion [9]. IL-27 has
been reported to limit TH1, TH2 and TH17 responses in various
models of infection and autoimmunity [10]. This immunosuppres-
sive role of IL-27 is particularly important to prevent excessive
inﬂammation, which may result in fatal organ damage or subse-
quent autoimmunity.
Data regarding the role of IL-27 in autoimmune diabetes are
scarce. A high serum level of IL-27 was detected in non-obese dia-
betes mouse, the animal model of autoimmune diabetes, and
blockade of IL-27 delayed the onset of diabetic splenocyte-trans-
ferred diabetes while IL-27 treated diabetic splenocytes promoted
disease onset [5]. IL-27 up-regulated pro-inﬂammatory cytokines
IFN-c and IL-17 and down-regulated anti-inﬂammatory cytokines
IL-4, TGF-b and IL-10.
Data in T1D in human are contradictory [11,12]. We have previ-
ously observed decreased expression of IL-21 and IL-17 receptors
in peripheral T lymphocytes and decreased Treg cell number in re-
cent-onset type 1 diabetes patients when compared with healthy
controls (submitted to publication). Considering that this could
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be involved in the pathogenesis of human autoimmune diabetes
and that genetic polymorphisms could inﬂuence the development
or severity of disease. Little is known about the association of alle-
lic variants in IL27, which encodes the p28 subunit of IL-27, with
autoimmune diabetes [11].
Therefore, the aim of this study was to investigate the inﬂuence
of genotypic and allelic variants in IL27 on susceptibility to T1D.2. Patients and methods
2.1. Subjects and study design
Patients with T1D (n = 318) according to the American Diabetes
Association classiﬁcation criteria and treated with two or more
insulin injections per day were recruited from Hospital das Clínicas
da Faculdade de Medicina da Universidade de São Paulo. Healthy
control subjects (n = 296) without family history of type 1 or type
2 diabetes or autoimmune disorders and with normal glucose and
HbA1c levels were recruited from the general population. This pro-
ject was approved by Institutional Board Review and all subjects
gave written informed consent.
Clinical and laboratory characteristics of the two groups are
shown in Table 1. There were no differences in gender or ethnicity.
T1D patients were younger, and, as expected, had lower C-peptide
levels, higher glucose and HbA1c levels and greater frequency of
pancreatic autoantibodies than control subjects (P < 0.001).
Sequencing analysis of the 50 proximal and entire coding re-
gions of IL27 was performed in 106 T1D patients and 98 control
individuals. This analysis was extended for variants c.-324C > T
(293 T1D and 196 control subjects) and rs34833 G/A (200 T1D
and 182 control subjects). Variant c.-964A > G (rs153109) was gen-
otyped in the entire cohort (318 T1D and 296 control subjects).2.2. Polymerase chain reaction (PCR) and sequencing analysis
Genomic DNA was extracted from peripheral blood leukocytes
using the salting-out method. The 50 proximal and entire coding re-
gions of IL27 (ENSG00000197272)were PCR-ampliﬁed using six pri-
merpairs in aVeriti Thermal Cycler (AppliedBiosystems, Foster City,
CA). Primer sequences and PCR conditions are available on request.
PCR products were puriﬁed using EXoSAP-IT (GE HealthCare
Life Sciences, Cleveland, OH) and sequencing reactions performed
using the BigDye Terminator v3.1 kit (Applied Biosystems). Direct
sequencing was performed on an ABI Prism Genetic Analyzer
3130  l (Applied Biosystems), and sequences were analyzed using
Chromas Lite 2 and Sequencher v4.8.Table 1
Clinical and laboratorial data of patients with T1D and control subjects.
Patients (n = 318)
(mean ± DP)
Controls (n = 296)
(mean ± DP)
P
Gender 189F/129 M 165F/131 M 0.39
Ethnic origin 250 C/67 NC 216 C/77 NC 0.16
Glucose (mg/dL) 183.6 ± 108.8 81.3 ± 8.4 <0.001
HbA1c (%) 8.7 ± 2.1 5.3 ± 0.6 <0.001
C-Peptide (ng/mL) 0.5 ± 0.4 2.3 ± 1.4 <0.001
Anti-GAD65 (U/mL) 9.9 ± 21.6 0.1 ± 0.1 <0.001
Anti-IA2 (U/mL) 5.0 ± 12.5 0.1 ± 0.2 <0.001
Age at diagnosis
(years)
10.93 ± 7.23 –
Diabetes duration
(years)
8.80 ± 8.90 –
Abbreviations: F, female; M, male; C, caucasian; NC, Not caucasian. HbA1c, Glycated
hemoglobin; Anti-GAD-65, glutamic acid decarboxylase antibody; Anti-IA2, tyro-
sine phosphatase antibody. Data are mean ± DP (standard deviation).2.3. Genotyping the c.-964A > G variant (rs153109) of IL27
A 221-bp fragment of the 50 proximal region of IL27 surrounding
variant rs153109 was PCR-ampliﬁed (forward 50-CATGGCCTCT-
ACAGAGCAGA-30 and reverse 50-GCTTGTGGCCTATAGGGTT-30
primers) and analyzed by restriction fragment length polymor-
phism (PCR–RFLP).
PCR products were subjected to digestion with TaqaI (New Eng-
land BioLabs, Ipswich, MA), yielding DNA fragments of 221 bp for
A/A genotype, 221/150/71 bp for A/G genotype, and 150/71 bp
for G/G genotype.
2.4. Autoantibodies
Autoantibodies against glutamic acid decarboxylase (GAD65
Ab), tyrosine phosphatase (IA2 Ab), thyroid peroxidase (TPO Ab),
thyroglobulin (TG Ab) and 21-hydroxylase enzyme (21-OH Ab)
were assessed by radioimmunoassay. Anti-nuclear antibodies
(ANA), anti-liver/kidney microsomal type 1 antibodies (anti-
LKM1) and anti-smooth muscle (ASM) were quantiﬁed by indirect
immunoﬂuorescence. Rheumatoid factor (RF) was evaluated using
nephelometry, and TSH receptor autoantibody (TRAb) using iodine
radioreceptor assays.
2.5. Statistical analysis
The distribution normality of numerical variables was veriﬁed
using the Kolmogorov–Smirnov test. Case and control samples that
did not signiﬁcantly depart from normality were compared using
Student’s t test and those that did not were compared using the
Mann–Whitney test. Genotype distribution was consistent with
Hardy–Weinberg equilibrium.
The association between nominal variables was determined by
chi-squared or Fisher exact test using the Statistical Package for So-
cial Sciences (SPSS) for Windows v16.0 (SPSS Inc., Chicago, IL). The
model of dominance with the presence or absence of variants was
used to analyze the allelic variants in IL27 in order to reduce the
number of classes and increase the statistical power of the sample.
Pairwise linkage disequilibrium between SNPs was evaluated with
the Cubex software [13]. The gametic phase of haplotypes and fre-
quencies of possible haplotypes for each individual were estimated
using the Bayesian method in PHASE v2.1.1 [14]. Haplotypes were
grouped according to their genealogical parenthood that was esti-
mated with the TCS 1.2.1 program [15].
P value 60.05 was considered statistically signiﬁcant. Critical p
values were corrected by the Bonferroni method for the analysis of
effect of genetic markers.
3. Results
3.1. IL27 variants in T1D and control subjects
Eight allelic variants were identiﬁed in the 50 proximal and cod-
ing regions of IL27, six of which had already been previously de-
scribed: rs153109 (A/G) in the promoter region, rs34833 (G/A)
and rs26528 (A/G) in intron 1, rs17855750 (T/G) in exon 2,
rs181206 (T/C) in exon 4 and rs40837 (T/C) in exon 5.
The two novel allelic variants were a heterozygous substitution
of cytosine by thymine located 324 bp upstream of IL27 transcrip-
tional start (c.-324C > T), found only in two patients, and a hetero-
zygous substitution of guanine by cytosine in exon 5, c.521G > C,
found in 6 T1D patients (5.7%) and 11 control subjects (11.6%).
Prediction analysis of putative transcription factor-binding sites
performed with TFSEARCH v1.3 did not identify loss or creation of
binding sites due to variant c.-324C > T. Variant c.521G > C results
in an amino acid change at residue 166 from glutamic to aspartic
Table 2
Frequencies of genotypes and alleles of the variants in IL-27 gene in patients with T1D
and control subjects.
Gene location Variant Genotype/alleles T1D n (%) Controls n (%) P
50 Proximal rs153109
A > G
AA 107(34.0) 97(33.1) 0.911
AG/GG 209(66.0) 196(66.9)
A 380(60.3) 341(58.2) 0.459
G 250(39.7) 245(41.8)
50 Proximal c.-347
C > T
CC 291(99.3) 196(100.0) 0.519a
TC 02(0.7) 0
C 582(99.6) 392(100.0) 0.527a
T 2(0.4) 0
Intron 1 rs34833
G > A
GG 185(92.5) 161(88.5) 0.220a
GA 15(7.5) 21(11.5)
G 383(96.2) 343(94.2) 0.259a
A 15(3.8) 21(5.8)
Intron 1 rs26528
A > G
AA 71(36.0) 66(36.3) 0.964
AG/GG 126(64.0) 116(63.7)
A 237(60.2) 213(58.5) 0.701
G 157(39,.) 151(41.5)
Exon 2 rs17855750
T > G
TT 95(89.6) 79(84.9) 0.393a
TG/GG 11(10.4) 14(15.1)
T 201(94.8) 174(91.6) 0.274a
G 11(5.2) 16(8.4)
Exon 4 rs181206
T > C
TT 66(62.3) 55(57.9) 0.626
TC/CC 40(37.7) 40(42.1)
T 167(78.8) 145(76.3) 0.638
C 45(21.2) 45(23.7)
Exon 5 rs40837
T > C
TT 38(35.8) 37(38.9) 0.758
TC/CC 68(64.2) 58(61.1)
T 131(61.8) 115(60.5) 0.875
C 81(38.2) 75(39.5)
Exon 5 c.6927
G > C
GG 99(94.3) 84(88.4) 0.203a
GC 06(5.7) 11(11.6)
G 206(97.2) 179(94.2) 0.221a
a Fisher’s exact test/Chi-square test.
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structure because both amino acids are chemically similar and
the residue is not well conserved among species, according to anal-
ysis with PolyPhen (Polyphen prediction of functional effect of hu-
man nsSNPs (http://genetics.bwh.harvard.edu/pph/; Boston, MA).
Allelic and genotype frequencies of IL27 variants did not differ
between patients and controls (Table 2). All the variants with min-
or allele frequency greater than 0.05 showed signiﬁcant pairwise
linkage disequilibrium, with their D’ value ranging from 0.5 to
1.0, in absolute values. Twenty-four haplotypes out of the 256 the-
oretically possible haplotypes with 8 biallelic SNPs were esti-
mated; the most frequent haplotypes were ACGATTTG (n = 217;
53.9%), GCGGTCCG (n = 61; 15.2%) and GCGGTTCG (n = 35; 8.7%).
To avoid classes with very small numbers, the haplotypes were
grouped in two classes (A and B), according to their genealogical
parenthood, as estimated with the TCS software. The grouped
genotypes did not differ in their frequencies between patients
and controls (p = 0.40, O.R. = 0.91). The haplotype genotypes also
did not interacted synergistically with the presence of major T1D
risk alleles (HLA – DR3 and – DR4) (p = 0.067).
There was no association between IL27 variants with gender or
ethnicity, nor with age at diagnosis of diabetes, presence of resid-
ual C-peptide levels in patients with recent-onset T1D or pancre-
atic (GAD Ab and IA2 Ab) and extrapancreatic autoantibodies
(TPO Ab, TG AB, 21-OH Ab, ANA, anti-LKM1, anti-ASM, RF, TRAb)
(data not shown).4. Discussion
To our knowledge, this is the ﬁrst report of investigation of
polymorphisms in the 50 proximal and coding regions of IL27 inrelation to T1D susceptibility in humans. Eight allelic variants were
identiﬁed, six of them already described in database repositories.
The two novel allelic variants did not seem to affect transcription
factor binding or protein structure. The ﬁnding that sequence vari-
ants in IL27 were rare suggests that it might have biologically
important function or that it is a relatively new molecule from
an evolutionary point of view.
Allelic, genotype and estimated haplotype frequencies of vari-
ants in IL27 did not differ between T1D patients and controls, sug-
gesting that allelic variants in this gene might not be associated
with susceptibility to T1D in humans, even when analyzed to-
gether with the major HLA-DRB1 risk alleles. Considering that IL-
27 increases the expression of IL-21 and IL-21 receptor [16] and
regulates Treg cell development, our data indicates that polymor-
phisms in IL27 are probably not related to our previous observation
of decreased Treg cell number and reduced IL-21 receptor expres-
sion in peripheral CD3+ and CD4+ T cells in recent-onset T1D.
The inﬂuence of IL27 variants on clinical and immunological
characteristics of patients with T1D was also investigated. There
was no association between IL-27 variants with gender or ethnical
origin of the population analyzed. In addition, no associations were
found between IL-27 variants with age at diagnosis of diabetes, the
presence of pancreatic and extra-pancreatic autoantibodies and
residual C peptide levels in recent T1D patients, suggesting that
IL-27 did not inﬂuence the humoral immune response or the de-
gree of disease aggressiveness. Since organ-speciﬁc autoantibodies
were frequent in T1D patients, especially TPO Ab, TG Ab and ANA
(22.9%, 23.4% and 20.3%, respectively), it could be speculated that
polymorphisms in IL27 might also not be associated with other
autoimmune diseases.
The rs153109 (A/G) and rs17855750 (T/G) variants of IL27,
which have been shown to be associated with susceptibility to
asthma [3], inﬂammatory bowel disease [7], chronic hepatitis B
virus infection [17] and chronic obstructive pulmonary disease
[18] in Asians, did not predispose to T1D in our cohort. Although
these disorders have a strong inﬂammatory component in which
IL-27 is expected to participate, the mechanisms behind its regula-
tion and the pathophysiology could be different to those of T1D.
It is known that asthma, COPD and ulcerative colitis are associ-
ated with Th2 immune response. Therefore as IL-27 can downregu-
late Th2 type cytokines, the presence of those polymorphisms
could interfere with its potential protective effect against such dis-
eases. On the other hand, as IL-27 promotes the development of
naïve CD4 + T cells into Th1 cells at an earlier stage of certain dis-
eases, one could hypothesize that the rs153109 AA genotype, by
causing greater IL-27 expression, was favoring chronic hepatitis B
virus infection and Crohn’s disease. So it was also expected to pre-
vail in type 1 diabetes patients. Further, by limiting Th1, Th2 and
Th17 responses, the IL-27 immunosuppressive role in preventing
excessive inﬂammation and autoimmunity could have been lost
in patients with the polymorphisms.
However, the discrepancy between our results in type 1 diabe-
tes and these diseases could also be due to the different ethnical
origin of the populations. The rs153109 AA genotype was less fre-
quent in our control group (33.1%) than in those from Asians (42.1–
60.7%), suggesting a regional effect.
In conclusion, our results suggest that allelic variants in the 50
proximal and coding regions of IL27 are not associated with predis-
position to T1D in our population.
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